Gastric cancer (GC) is the 3rd deadliest cancer worldwide, due to limited treatment options and late diagnosis. Human epidermal growth factor receptor-2 (HER2) is overexpressed in~20% of GC cases and anti-HER2 antibody trastuzumab in combination with conventional chemotherapy, is recognized as standard therapy for HER2-positive metastatic GC. This strategy improves GC patients' survival by 2-3 months, however its optimal results in breast cancer indicate that GC survival may be improved. A new photoimmunoconjugate was developed by conjugating a porphyrin with trastuzumab (Trast:Porph) for targeted photodynamic therapy in HER2-positive GC. Using mass spectrometry analysis, the lysine residues in the trastuzumab structure most prone for porphyrin conjugation were mapped. The in vitro data demonstrates that Trast:Porph specifically binds to HER2-positive cells, accumulates intracellularly, co-localizes with lysosomal marker LAMP1, and induces massive HER2-positive cell death upon cellular irradiation. The high selectivity and cytotoxicity of Trast:Porph based photoimmunotherapy is confirmed in vivo in comparison with trastuzumab alone, using nude mice xenografted with a HER2-positive GC cell line. In the setting of human disease, these data suggest that repetitive cycles of Trast:Porph photoimmunotherapy may be used as an improved treatment strategy in HER2-positive GC patients.
Gastric cancer (GC) is the 3rd deadliest oncologic disease worldwide, mainly due to limited treatment options and late diagnosis. 1, 2 Surgery is the most efficient therapeutic strategy for improving patients' survival; however it is only effective in early disease stages. 1 As most patients present with advanced disease, conventional chemo-and radio-therapy are the only options available and present overall survival rates below 1 year. 3 Anti-HER2 therapy, based on monoclonal antibody trastuzumab combined with conventional chemotherapy, was introduced for the treatment of metastatic GC in Europe in 2010. 3, 4 Chemo-na€ ıve patients with unresectable GC that demonstrate HER2 overexpression and/or erbb2 amplification are currently eligible for this treatment regimen.
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HER2-antibody treatments act through the following mechanisms: (i) blocking of HER2 signalling pathway leading to apoptosis induction; (ii) inhibition of prosurvival signals, and; (iii) induction of antibody dependent cellular cytotoxicity (ADCC). 6, 7 Because of this multiple mode of action, overall survival of advanced GC patients improved 2.7 months when trastuzumab was combined with conventional chemotherapy, compared to chemotherapy alone (ToGA trial). 3 These results, although modest, are the best obtained so far regarding targeted therapy in GC. 8 An attractive and promising modality to further improve the treatment of gastrointestinal tract malignancies is photodynamic therapy (PDT). 9, 10 PDT acts via the activation of photosensitizers (PS) using light of certain wavelength that correspond to the maximum absorbance of the selected PS. 11 The combination of PS, tissue oxygen and light, generate reactive oxygen species and cause oxidative damage leading to cell death. 11 PDT has been successfully applied in the treatment of oesophageal cancer, non-small cell lung cancer, bladder cancer and non-neoplastic diseases such as psoriasis and acne. 11, 12 The clinical procedure of cancer PDT consists of three steps: intravenous (IV) or topical administration of PS; a variable period of time when patients remain in a dark to allow for PS bio-distribution, whilst avoiding potential light-induced side effects in normal tissues; and selective irradiation of the lesion. 11 The binary selectivity of PDT is achieved via preferential intratumour accumulation of PS and selective irradiation of the tumour area. 11 Unfortunately, most commonly applied PSs used for PDT accumulate not only in tumours but also in healthy tissues, resulting in severe side effects like prolonged skin and eye photosensitivity. 12 The use of PSs conjugated with monoclonal antibodies (PIC-photoimmunoconjugate) allows specific targeting and photosensitization of receptor positive cells only, 13 and also minimizes the risk of side effects. To obtain a stable and active antibody conjugate, the PS should be covalently linked to the antibody. Some studies have tested the use of a near-infrared (NIR) PS, siliconphthalocyanine IR-700, combined with human monoclonal antibodies against CEA or HER2, to treat GCs that overexpress these targets. [14] [15] [16] Such studies demonstrated rapid cell death and significant inhibition of tumour growth after photoimmunotherapy (PIT). [14] [15] [16] In these studies, the number of PS molecules conjugated to each antibody was confirmed, but the conjugation sites and tropism of PS molecules to specific antibody residues were not assessed. This is particularly important, as the coupling of PS most likely occurs at lysine residues of the antibody, and if lysine-conjugation occurs at the antigen binding site this results in loss of immunoreactivity. 13 Another important issue is the photodynamic activity of PICs which is increased if using positively charged PS. These cationic PSs have an additive effect on the phototoxicity, likely due to their improved cellular binding and intracellular accumulation, as a result of the overall net negative charge of the external cell membrane of malignant cells. 17 Moreover, the porphyrin used in this study becomes activated through red light absorption, a feature known to provide up to 1.0 cm in depth of tissue penetration. 13 In the present work, we developed and characterized a new PIC by combining a water soluble cationized PS with trastuzumab (Trast:Porph), and demonstrated its improved efficiency to specifically eliminate HER2-positive GC cells following photodynamic therapy when compared to trastuzumab alone, both in vitro and in vivo.
Materials and Methods

Reagents
All reagents are from ThermoFisher Scientific (Waltham, MA, USA), unless otherwise stated. (Fig. 1a) was performed as described in the literature 18, 19 and as shown in Supporting Information Figure S1 . One equivalent of trastuzumab (Genentech, South San Francisco, CA), 1 mg mL
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, was mixed with 10, 20, 30 or 40 equivalents of Nhydroxysuccinimide DMSO stock of cationized porphyrin. The conjugation reaction was conducted in PBS and the DMSO concentration was 3%. Collected fractions containing both protein and porphyrin, as determined by UV-Vis, were purified by gel filtration on PD10 columns (GE Heathcare) and dialyzed overnight with MWCO 10 kDa cassettes. Protein concentration of the conjugate was determined using the BCA kit, according to the manufacturer's instructions.
What's new?
HER2 is overexpressed in many gastric cancers (GC). The anti-HER2 antibody trastuzumab has been a useful addition to standard chemotherapy in HER2-positive, metastatic GC. In this study, the authors linked trastuzumab with a light-reactive porphyrin to create a novel photoimmunoconjugate drug. When it was used for photodynamic therapy (PDT), this molecule showed promise both in vitro and in xenograft studies. But would it improve treatment results in human HER21 GC patients? With repetitive cycles of Trast:Porph PDT, the answer appears to be "yes."
Characterization of Trast:Porph SDS-PAGE with 10 mg of protein/well was performed, the gel visualized in UV-Vis light for detection of porphyrin fluorescence. Protein was detected after overnight staining with Coomassie blue. Immunoreactivity of the Trast:Porph conjugation products was assessed using an anti-HER2 ELISA and compared with that obtained for native trastuzumab (as detailed in Supporting Information Materials and Methods).
The sites of porphyrin conjugation to trastuzumab were characterized by mass spectrometry analysis using a MALDI-TOF/TOF mass spectrometer (4800 Plus, SCIEX, Framingham, MA). For intact protein analysis, the IgG conjugate was diluted 1:4 (v/v) in MALDI matrix (sinapinic acid 10 mg mL 21 , 50% acetonitrile, 0.1% trifluoroacetic acid), spotted onto a target plate, and analyzed in linear positive mode. Mass spectra were calibrated with commercially available IgG (SCIEX, Framingham, MA). The estimated number of porphyrin molecules per molecule of trastuzumab, for each molar ratio tested, was obtained comparing the mass difference between the conjugated and unconjugated molecules. For conjugated lysines mapping, we analysed the trastuzumab and PIC heavy chains, as lysine residues are present in CDR regions of heavy chains and not in light chains. We performed SDS-PAGE in reducing and denaturing conditions, to separate light and heavy chains. Heavy chains were cut from the gel, washed, reduced with DTT, alkylated with IAA, and enzymatically digested with trypsin (two independent synthetic batches of conjugate) and chymotrypsin (third independent batch). 20 Peptide mass spectra were acquired in reflector positive mode and data analysis was carried out using MS-Bridge software (ProteinProspector, University of California, San Francisco, CA).
Cell lines and culture conditions
Human GC cell line NCI-N87 was purchased from the American Type Culture Collection (ATCC, Rockville, MD). MKN74 was purchased from the JCRB Cell Bank (Japanese Collection of Research Bioresources Cell Bank). GP202 cell line was established at Ipatimup. 21 Cell identification was confirmed by STR analysis and cells were confirmed to be free of mycoplasma contamination. For details see Supporting Information Materials and Methods. GP202 cells/well were plated in 96-well plates, incubated for 24 hrs, and incubated with Trast:Porph, native trastuzumab or unconjugated porphyrin for 90 min at 378C. Cells were then washed with PBS, incubated with phenol-red free RPMI 1640 media, and exposed to a total delivered light dose of 40 J cm 22 . After PDT, treated cells were incubated for an additional 24 hrs and the treatment efficiency was tested as described below.
The PIT effect was also assessed following HER2 blocking (by preincubating cells with 75 mg mL 21 trastuzumab for 90 min at 378C), prior to performing the PIT protocol.
Cell survival and viability assays
To determine the PIT effect on cell survival, we used a resazurin-based assay (PrestoBlue Cell Viability Reagent) and the live/dead viability assay, according to the manufacturers' instructions. For details see Supporting Information Materials and Methods.
Photoimmunotherapy regimen in vivo
All procedures involving animals were performed in accordance with the European Guidelines for the Care and Use of Laboratory Animals, Directive 2010/63/UE, Portuguese National Regulation published in 2013 (Decreto-Lei n.8 113/ 2013 de 7 de Agosto) and approved by the local Ethics Committee of the Instituto de Investigação e Inovação em Sa ude-i3S (Porto, Portugal). The authors involved in these experiments have an accreditation for animal research given from Portuguese Veterinary Direction (Ministerial Directive 1005/92). NIH(S)II: nu/nu mice, strain described by Azar et al., 22 were generated under Ipatimup supervision. Male nude mice aged 6 to 9 week-old were injected subcutaneously, bilaterally, in the flanks, with 5 3 10 6 NCI-N87 cells in Matrigel (Corning, Bedford, MA). Four mice were used for Trast:Porph biodistribution assay and 24 for the PIT experiment, as described in Supporting Information Material and Methods. When tumours reached 100-150 mm 3 , mice were randomly assigned into 3 groups and injected in the tail vein with: (i) vehicle (PBS); (ii) 8 mg kg 21 trastuzumab and; (iii) 8 mg kg 21 Trast:Porph. At 24 hrs after the injection, animals were anesthetized, the left tumour from each mouse was exposed to 100 J cm 22 of light (Luma Care TM , LC-122, Newport Beach, CA) using a filter cut off below 550 nm. The right tumour from each mouse was protected from irradiation and served as an internal control. A second cycle of PIT, with two rounds of irradiation, was performed as described in the Supporting Information. When tumour volume reached 1000 mm 3 , the experiment was terminated and mice were humanely euthanized (with anaesthesia and cervical dislocation), necropsies were performed and tumours/animal organs removed/processed for histology and immunohistochemistry.
Data analysis
Statistical data analysis was carried out using software Graph Pad Prism (Graph Pad Software Inc., La Jolla, CA). The Student's t test was used to compare the conjugation or treatment effects with controls. The values are represented as mean 6 SD. The Mann-Whitney test was used to compare the different experimental arms in vivo. Level of significance was set at values *p < 0.05, **p < 0.01 and ***p < 0.001.
Results
Development and characterization of a photoimmunoconjugate based on water soluble porphyrin and trastuzumab (Trast:Porph)
We synthesized the water soluble cationized porphyrin (Supporting Information Fig. S1 ), as depicted in Figure 1a , and coupled it to trastuzumab (Fig. 1b) . 23, 24 The high purity of conjugate ensures that, upon systemic administration and irradiation, the typical unspecific toxicity resulting from free porphyrin impurities will not be observed. 25, 26 There are 92 lysines in the structure of trastuzumab that are potential sites for porphyrin conjugation. 27, 28 To ascertain the best strategy for photoimmunoconjugation, we considered that highly loaded PICs have: (i) a high drug antibody ratio (DAR) and impaired immunoreactivity, due to the possible binding of payload to epitope recognizing regions; 25 (ii) unfavorable pharmacokinetics and faster clearance, 29 and; (iii) lower efficiency of singlet oxygen generation, due to self-quenching of triple state by the close proximity of photosensitizer molecules onto the antibody. 30 We designed an optimization procedure to identify the best antibody-porphyrin conjugation ratio that would allow preservation of the antibody immunoreactivity. Purification of these conjugates revealed that protein retrieval decreased with increasing conjugation ratios, namely 93% of conjugate was recovered for 1:10 ratio, 46% was recovered for conjugation ratios of 1:20 and 1:30, while for the 1:40 ratio the percentage of protein retrieval was merely 3.3% (data not shown). Immunoreactivity of conjugation products was assessed, by ELISA, and only the 1:10 molar ratio displayed no significant decrease in immunoreactivity (Fig. 1c) .
The estimated number of porphyrin molecules per molecule of trastuzumab (DAR) for each conjugation product, was obtained by MALDI mass spectrometry analysis. The experimental mass of the unconjugated trastuzumab was m/z 148,935. For the Trast:Porph molar ratio 1:10, we observed a conjugate mass at m/z 150,975. This increase is consistent in the conjugation of ca. 3 porphyrins (free MW 706.81, conjugated MW 689.80) per antibody molecule. For the molar ratios of 1:20 and 1:30, ca. 6 (observed conjugated mass at m/z 153,262) and ca. 7 (m/z 153,792) porphyrins were conjugated per antibody, respectively (Fig. 1d , and Materials and Methods section for technical details). These results show that the molar ratio of Trast:Porph 1:10 provides the highest protein retrieval in the purification reaction, retains immunoreactivity similar to that of the native antibody, and presents an optimal DAR, according to published data. Therefore, we chose the 1:10 conjugation ratio for further biological studies and will name it as Trast:Porph for the remaining part of the manuscript.
SDS-PAGE analysis confirmed the presence of porphyrin onto trastuzumab, as a slight shift of the Trast:Porph into higher molecular weight is observed, in comparison with native trastuzumab (Fig. 1e, left panel) . We confirmed the acquisition of fluorescence upon conjugation and the lack of noncovalently bound porphyrin present in the Trast:Porph (Fig. 1e, right panel) . 25 According to the Kabat database 31 trastuzumab contains 4 lysines localized in two heavy chains of immunoglobulin CDRs (Supporting Information Fig. S2 ). To characterize the sites of porphyrin conjugation to trastuzumab, we performed proteomic analysis of peptides, from heavy chains isolated from SDS-PAGE (Supporting Information Fig. S3 ), obtained via tryptic and chymotryptic digestion from both native antibody and the conjugate (Supporting Information File 12) . Although we could not identify peaks corresponding to peptides bearing cationic porphyrin-conjugated lysines, our data analysis clearly and recurrently revealed a constitutive decrease in signals from peptides containing certain lysine residues. This result, although indirect, seems to indicate that the presence of porphyrin at specific lysine residues may impair proteolytic activity of the enzymes chosen for analysis. To address this possibility, we created classification criteria for the peptides obtained from tryptic and chymotryptic digestion into three classes: "conjugated lysine peptides," "non-conjugated lysine peptides" and "non-lysine peptides" (Fig. 1f , Supporting Information File1). This comparison revealed that the class of "conjugated lysine peptides" was statistically different from the remaining two classes of peptides (p < 0.0001) (Fig.  1f) . This result supports our hypothesis that some specific lysines from trastuzumab become recurrently conjugated with porphyrin, impairing trypsin and chymotrypsin cleavage, and become less represented in the Mass Spectrometry data. We identified 6/32 lysines present in the heavy chain of trastuzumab as the most prone for conjugation, and created a schematic model of their localization (Fig. 1g) . Four out of these six lysines are located in the Fc region of trastuzumab heavy chain. Two were identified in the Fab heavy chain region including one in the CDR region of the antibody. The constant profile of peptides obtained by tryptic and chymotryptic digestion of the trastuzumab heavy chain, indicates that porphyrin conjugation occurs at these preferential lysine residues.
Trast:Porph binds specifically to HER2-positive cells in vitro and internalizes to the lysosomal compartment To test the specificity and immunoreactivity of the Trast: Porph in vitro, we used three GC cell lines with varying levels of HER2 expression: NCI-N87 (membranous expression), MKN74 (weak cytoplasmic expression) and GP202 (absence of HER2 expression), as confirmed by fluorescence microscopy (Fig. 2a) . In vitro immunoreactivity, analysed by flow cytometry, showed that both Trast:Porph and native trastuzumab selectively recognized the HER2-overexpressing NCI-N87 cells (Fig. 2b) . However, there is a 40% decrease fluorescence intensity of the Trast:Porph compared to native trastuzumab stained cells (Fig. 2c) . When analysing NCI-N87 cells incubated with trastuzumab or Trast:Porph for detection of native trastuzumab or Trast:Porph, by fluorescence microscopy, it was clear that all cells were labelled (Fig. 2d) . This demonstrated that these molecules are bound to all cells, as already indicated by 
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Korsak et al. results in Figure 2b . Still, the decrease in the labelling intensity of HER2-positive cells may be justified by the following reasons: porphyrin molecules bind at the trastuzumab CDR region and impair to some extent antigen recognition, and/or; the antibody used to detect the Trast:Porph and native trastuzumab finds some of its binding moieties in the Fc region conjugated to porphyrin, and fails, to some extent to detect trastuzumab. Despite the abovementioned issues, the Trast:Porph specificity and immunoreactivity was demonstrated by two independent techniques (Figs. 2b and 2d ) and, importantly, binds to all HER2 expressing cells like native trastuzumab (Fig. 2c) . Moreover, we observed intracellular localization of Trast:Porph, which was not evident in cells incubated with native trastuzumab (Fig. 2d) . Given the available literature showing that introduction of multiple positive charges onto biomacromolecules increases cellular endocytosis rate, 17, 32 we hypothesized that the conjugation of trastuzumab with a cationic porphyrin was promoting intracellular accumulation of the Trast:Porph. We used confocal microscopy with concomitant staining of trastuzumab and the lysosomal marker LAMP1, to determine whether Trast:Porph undergoes the well-known endosome-lysosomal internalization pathway. 33 Trast:Porph, but not native trastuzumab, was clearly identified intracellularly and showed to co-localize with LAMP1 in the lysosomal compartment (Fig. 2e) . Moreover, Trast:Porph internalization was very fast, being observed 10 min after incubation of cells with the PIC (Supporting Information Fig. S4a) , and persisted for at least 180 min (Supporting Information Fig. S4b ).
Considering the above described results, we irradiated cells 90 min after their incubation with the Trast:Porph in the subsequent experiments.
Trast:Porph potentiates the photocytotoxic effect in HER2-positive GC cells in vitro
We then aimed at evaluating the Trast:Porph mediated PIT, in the elimination of HER2-positive GC cells. Photocytotoxicity was specifically observed in the HER2-positive GC cell line NCI-N87, while no effect was observed in the remaining HER2-negative GC cell lines (Fig. 3a) , proving PIC specificity for HER2 membranous expression. Trast:Porph photocytotoxicity, in NCI-N87 cells, was concentration dependent, reaching 70% for the highest concentration tested. Irradiation alone, native trastuzumab alone, irradiation following unconjugated porphyrin treatment and Trast:Porph treatment without irradiation did not influence cell survival, supporting these conditions as adequate (Fig. 3a) . We performed the Live/Dead assay upon irradiation using NCI-N87 and MKN74 cells. NCI-N87 cells displayed impaired cellular membrane 6 hrs after PIT treatment (Fig. 3b) , an effect that persisted at 24 hrs (Supporting Information Fig. S5) . Moreover, the typically observed NCI-N87 cell clusters seem to disappear at 24 hrs, suggesting loss of proliferation ability (Supporting Information Fig. S5 ). We also verified that 3 hrs after PIT, NCI-N87 cells displayed evidence of cell swelling, which is characteristic of photodynamic damage (Supporting Information Fig. S6 ). These effects were, again, specific for HER2 expressing cells as the HER2 negative cell line was not affected (Fig. 3b, Supporting Information Figs. S5 and S6 ). We then analysed PIT induced apoptosis (by flow cytometry) 3 hrs after irradiation. No features related to early stages of apoptosis were observed whilst most cells demonstrated positive PI staining, characteristic of necrosis or late stages of apoptosis (Supporting Information Fig. S7 ). The cell morphology and PI staining results indicate that cellular membrane damage occurs very quickly as a consequence of PIT. Taken together, the results described above suggest that cell membrane is the organelle of primary damage and lysosomal disruption likely contributes to the observed cytotoxic effect.
To reinforce that the photocytotoxic effect of PIT is specifically mediated by membranous HER2, we blocked the endogenous HER2 receptor via incubation with native trastuzumab in NCI-N87 cells, prior to PIT and observed a significant photocytotoxicity inhibition (Fig. 3c) . This experiment demonstrated that photosensitization and cytotoxicity is mediated by membranous HER2, and importantly suggests that passive uptake of the Trast:Porph bearing positive charge will probably not induce a cytotoxic effect in non-HER2 expressing cells.
Photoimmunotherapy with Trast:Porph delays tumour growth compared to native trastuzumab
To test the PIT efficiency in vivo, we generated a nude mice model xenografted with HER2-positive NCI-N87 cells. Biodistribution of Trast:Porph was assessed and the conjugate detected in tumours (Fig. 4) , regardless of the injection route being intravenous or intratumoral (data not shown). In contrast, no PIC was detected (only auto-fluorescence was observed) in any of the mouse organs collected (Supporting Information Fig. S8 ). These results demonstrate that the PIC can selectively recognize the HER2 expressing tumour cells in vivo, even when injected in circulation. For subsequent experiments, IV injection was selected since it proved to be effective regarding tumour biodistribution and is the most commonly route used for ADCs administration in the clinic.
We next investigated whether PIT could inhibit tumour growth in vivo following the treatment scheme indicated in Figure 5 (upper panel). Seven days after the beginning of PIT, we observed a tumour growth kinetics delay specifically in the Trast:Porph irradiated experimental group. At Day 10 after the beginning of PIT, this difference in tumour volume and growth kinetics became statistically significant (Fig. 5 , middle and lower panels). Mice were kept for another 5 days without any further treatment, to evaluate whether two PIT cycles would be sufficient to stabilize tumour growth, and the experiment was completed at Day 14 (11 days after the last IV administration). Mice from the Trast:Porph irradiated experimental arm maintained a lower tumour volume than tumours from all other experimental arms, particularly evident at Day 10, however, this difference was not significant when mice were kept out of PIT treatment for 9 days (Day 14 in Fig. 5 , middle and lower panels; Supporting Information Fig. S9 ). Indeed, tumour growth kinetics started being similar in all experimental arms 6 days after completion of the last PIT cycle (Day 11). These results indicate that although two cycles of PIT represent an efficient strategy in delaying tumour growth of HER2-positive tumours, it would be preferable to perform additional PIT cycles.
Histological analysis of HER2-positive xenograft tumours suggests a shared photoimmunocytotoxic effect in vitro and in vivo
We searched for the presence of Trast:Porph and native trastuzumab within tumours, after the in vivo experiment was completed, to infer about the in vivo elimination of Trast: Porph and native trastuzumab. We could detect trastuzumab in tumours from the experimental arms treated with native trastuzumab, but not in tumours from the experimental arms Fig. S10 ). Additionally we could not detect the presence of Trast:Porph in organs collected from mice after the experiment was completed (Supporting Information Fig. S11 ). Interestingly, we did not observe PIC accumulation in the lungs (Supporting Information Figs. S8 and S11) unlike reports where cationic PICs lung accumulation has been observed. 25, 35 Several hypothesis may be raised to explain the lack of staining in Trast:Porph treated tumours: (i) the elimination of the Trast: Porph is faster than the elimination of native trastuzumab;
(ii) conjugation of trastuzumab with the porphyrin affects the half-life of the antibody or (iii) cells targeted by the Trast: Porph died and the excised tumour is the result of the growth of non-Trast:Porph targeted cells. However another set of experiments would be needed to clarify this aspect.
All tumours displayed similar histology and proliferation index (Supporting Information Fig. S12 ), supporting that 11 days after the last PIT, tumours recover the ability to grow and proliferate and that additional PIT cycles should be performed with shorter intervals between them. In an attempt to understand whether the cytotoxic mechanism identified in vitro (cytoplasmic internalization of Trast: Porph to the lysosomal compartment) would also occur in vivo, we analysed tumours excised from mice 24 hrs after Trast:Porph injection. Staining of these tumours with an anti-HER2 antibody revealed a high intensity staining at the membrane (Supporting Information Fig. S13 ; see orthogonal images on left panel). In contrast, when the consecutive cut was stained with an antibody for Trast:Porph, the PIC was mainly localized at the cytoplasm (Supporting Information Fig. S13 ), corroborating the in vitro results. However, due to technical reasons, we were not able to complete the co-localization analysis of LAMP1 and Trast:Porph, in tumour material.
Discussion
Photodynamic therapy is now an approved cancer treatment, 11 although in the management of gastrointestinal tumours this treatment modality is only marginally used. The main reasons for this are: (i) the difficulties in setting multicentre randomized clinical trials that show unequivocally the benefits of this treatment modality; (ii) the high photosensitization of eyes and skin when unspecific photosensitizers are used, and (iii) the lack of formal clinical evidence that photosensitizers conjugated to antibodies are tumour specific and more efficient than the unconjugated antibodies approved for targeted therapy.
The present work contributes with increasing evidence supporting the use of these emerging targeted photoimmunotherapies (PIT) as supportive treatment for cancer patients (Fig. 6) . 18 We chose HER2-positive GC as a study model, as trastuzumab has been accepted as targeted therapy for patients with advanced GC, that are positive for HER2 expression, with survival benefit and good tolerance in these patients. 3 However, the presently HER2 targeted therapy still demonstrates limited efficiency, being the main reason the fact that it has been directed to patients with HER2-positive recurrent and metastatic disease, whose clinical condition does not support surgical intervention. Although in most patients, the disease is already far from its original location, it is also true that most of these patients retain the cancerbearing organ. This constitutes an opportunity to use HER2-targeted PIT that can be administered intravenously combined with endoscopy-based irradiation, likely increasing the effect of this targeted therapy in the stomach and the frequently involved duodenum. Moreover, despite complicated, it may be also possible to reach at least the pancreas and liver using fibre optics, and eliminate HER2-positive gastric cancer cells that often metastasize to these organs.
The aim of our study was to develop and characterize a new photo-immunoconjugate based on porphyrin conjugated to trastuzumab (Trast:Porph), and test its efficiency to specifically eliminate HER2-positive GC cells and xenograft tumours. Our work demonstrates that it is possible to improve the efficiency of the currently clinically approved HER2 targeted therapy using trastuzumab.
We successfully completed the optimization and characterization of a Trast:Porph PIC, with particular emphasis on conjugate quality, optimal ratio of trastuzumab to porphyrin in the conjugation reaction, description of recurrent sites of porphyrin conjugation and preservation of immunoreactivity of the antibody upon conjugation. We quantitatively measured the immunoreactivity of the Trast:Porph and confirmed an acceptable loss of immunoreactivity. 33 Also, DAR of obtained conjugate was calculated to be 3, which is in accordance to data reported in the literature. 18, 36 The mass spectrometry analysis of the Trast:-Porph allowed to determine the lysine residues that were most prone for porphyrin conjugation. To the best of our knowledge, this is the first detailed description of this process for PICs. We were able to show optimal characteristics of Trast:Porph using simple N-hydroxysuccinimide approach not involving highly specialized approaches, such as click-chemistry. 37 The in vitro analysis herein performed, using three GC cell lines with different HER2 expression levels, demonstrated that Cancer Therapy and Prevention binding of the Trast:Porph was highly selective and photocytotoxicity was observed only in HER2-positive cells. We also observed that for the same concentration of trastuzumab and Trast:Porph, only the latter induced a high level of photocytotoxicity. This phenomenon of cytotoxicity in lower concentrations of the conjugated antibodies were also observed for antibody-toxin conjugates. 9 These results evidence clear advantages of Trast:-Porph in relation to native trastuzumab or the regular photosensitizers: (i) the PIC is efficient at lower doses of antibody; (ii) the covalent binding of the porphyrin to the antibody decreases the risk of dissociation, minimizing off-target effects and hyperphotosensitivity in exposed organs and tissues, and (iii) the PIC selectively binds cancer cells overexpressing the antibody target. These advantages highlight the increased safety of PIT compared to other currently clinically approved therapeutic approaches. This may likely demonstrate that conjugation of a porphyrin together with irradiation potentiates the trastuzumab mediated effect for lower antibody concentrations, even without the contribution of the immunological system, that is, a well-known partner in the HER2-mediated cell elimination in vivo. 6, 38, 39 Regarding the mechanisms underlying PIT efficiency, the observed analogous membranous localization of the PIC and native trastuzumab nicely explains why the HER2 signalling blockade occurs. However, it was also evident that the Trast: Porph was fast and efficiently internalized into the lysosomal compartment. PIC internalization into the lysosomes and lysosomal-disruption after irradiation may trigger necrosis, due to the release of the acidic content of lysosomes. PIT did not induce early stages of apoptosis, with only later stages of apoptosis or necrosis being observed, suggesting that our PIT strategy triggers necrosis in vitro. Our data is supported by previously reported findings in other cancer models, showing that lysosomal localization of PIC improved the outcome of PIT in vitro 40, 41 and in vivo. 42 However, it is important to emphasize that the cellular membrane is the organelle of primary damage responsible for robust cell death in vitro.
We also tested the Trast:Porph in vivo through application of PIT in nude mice xenografted with HER2-positive GC cells, that develop clear tumour masses mimicking those present in GC patients. In a well-controlled experimental setting, we observed tumour growth delay exclusively in irradiated tumours of Trast:Porph treated mice. The in vivo effect Trast:Porph and irradiation, although not as prominent as that obtained in vitro (100% penetration of light in a single monolayer of cells), was clearly more impressive than that obtained with native trastuzumab. Indeed, native trastuzumab alone did not decrease or refrain tumour growth with the antibody concentrations used, supporting our in vitro data and highlighting the advantages of using trastuzumab conjugated with photosensitizers. Tumour growth was refrained after two cycles of PIT, however regrowth commenced 2-5 days after the last PIT cycle, demonstrating that several cycles, with a maximum of 5 days interval between them, should be applied in order to maintain growth inhibition or lead to complete tumour remission. This notion is supported by recent results indicating that recurrences occur if repetitive cycles of PIT are not performed. 36 We should highlight the fact that 2/9 irradiated tumours from Trast:Porph treated mice grew at the same rate that Trast:Porph treated but not irradiated animals (Supporting Information Fig. S9-red  squares) . The most likely explanations are that: these tumours were already larger than the remaining when the treatment started and/or, the penetration of Trast:Porph conjugate into the tumour was limited due to unequal extravasation and non-homogeneous tumour-vasculature. If translating this to the setting of human disease, our data and published reports suggest that PIT, with repetitive cycles of Trast:Porph (coupled with endoscopic light delivery), might be of special use as a treatment strategy, at least in GC patients with inoperable disease. The treatment modality certainly needs to be optimized depending on each type of cancer or patient individually. For instance, PIT has been used as an adjuvant treatment upon debulking surgery of pancreatic cancer in a PDX model, 43 and it has been shown very promising results when combined with conventional chemotherapeutic, such as cisplatin 44 or 5-fluorouracil. 16 Our expectation for the proposed modified, and apparently more efficient anti-HER2-based therapy, is that HER2-positivity is screened for in biopsies from all GC patients, allowing those with early disease stages who test positive for HER2, to be treated with endoscopic PIT, or with PIT associated with endoscopic ultrasonography (EUS). For HER2-positive early stages with regional nodal involvement, it would be important to consider performing PIT at the time of surgery, as well as after surgery in case of partial gastrectomy, to decrease the local recurrence risk.
The phase III trial of RTOG 1010 is evaluating the addition of trastuzumab with chemoradiation in the neoadjuvant fashion. Patients with stage T1, N1-2 or T2-3, N0-2 gastrooesophageal adenocarcinoma or oesophageal carcinoma are eligible to participate in that study. It would be interesting to be able to test the anti-HER2-based PIT herein proposed in a similar design.
Conclusions
Altogether, our results indicate that Trast:Porph mediated PIT potentiated cytotoxicity specifically in HER2-positive cells, hence minimizing possible PIT-induced side effects to non HER2-expressing cells. Importantly, Trast:Porph mediated PIT was more effective in delaying tumour growth in vivo when compared to native trastuzumab alone (Fig. 6 ). This higher cytotoxicity seems to be amplified through subcellular accumulation of the Trast:Porph PIC in the lysosomal compartment, that becomes efficiently activated by red light, potentiating massive tumour cell death. Our report contributes to the body of literature available on this subject and encourages for further developments and consideration of PIT in the clinical setting.
